| Name | Title | Contact Details |
|---|
HPI redefines what is possible with self-funded health plans. As a third-party administrator, we partner with health plan brokers and employers to provide innovative self-funding strategies and customized plans tailored to each clients needs and population. Our solutions give employers greater cost transparency and control, while elevating the member experience.
Richelieu is Canadas leading distributor, importer, and manufacturer of specialty hardware and complementary products - and also ranks among the top players in its specialty in North America. We are the leading driver of worldwide innovations in functional and decorative hardware. We provide manufacturers and retailers with a UNIQUE mix of more than 130,000 different items in a host of categories: decorative hardware · kitchen accessories · lighting systems · functional and decorative mouldings · functional hardware · ergonomic workstations · finishing and decorating products · high-pressure laminates · veneer sheets and edgebanding products · screws and fasteners... We take pride in serving more than 110,000 customers across North America, in two major markets: * Manufacturers o Kitchen and bathroom cabinet manufacturers o Home and office furniture manufacturers o Residential and commercial woodworking industry, etc. * Retailers o Purchasing groups o Small and medium-sized hardware stores o Renovation superstores 113 distribution centers in North America. Some 3,000 people work throughout the network, more than half are specialized in sales and marketing, so as to provide our extensive base of loyal customers with first-class service. Richelieu Hardware Ltd. is a public company listed on the Toronto Stock Exchange (TSX) under the ticker symbol RCH.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
OakStar Bank strives to prove each day that banking can and should be a joyful and fun experience. By creating a unique work culture that is rooted and cultivated throughout every aspect of the bank, OakStar team members love what they do, love the people they work with, and love serving the community. The banks commitment to their values and their culture has resulted in the creation of a uniquely new banking experience that is comfortable, warm, and completely relationship based… ultimately a place where customers look forward to going. OakStar Banks passion is to create a positive difference for its customers and leave a long-lasting legacy in the community.